Clarus
Venture capitalCambridge · 6 people tracked
Find your way into Clarus
Fund manager profile
Clarus is a venture fund manager based in Cambridge. SEC filings show 4 venture funds on record, most recently Clarus IV-C, L.P. ($880M offering) filed May 2017.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 6 people
from public directoriesWhat they invest in
from 12 of 12 portfolio companiesBiotech ×11Healthtech ×5Medical Devices ×2AI & Machine Learning ×1Deep Tech ×1Hardware ×1
HQs:United States×11
Investments · 12 tracked
founders shown can be your intro pathBy year:2018 · 22017 · 12016 · 62015 · 211 dated
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
BiotechHealthtechLa Jolla, US
Kenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Michael J. Dunn(Executive Officer)inStephen Bardin(Chief Financial Officer)in
Board seatEmmett Cunningham· per SEC Form D · $80.4M raise · filed Jun 2018
Co-investorsAisling CapitalSanderling VenturesClarus LifesciencesOrbiMed
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
Board seatNicholas GalakatosNicholas G. Galakatos· per SEC Form D · $10M raise · filed Jun 2019
Co-investorsAvoro Capital AdvisorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstone+6 more
Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.
BiotechHealthtechSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)
Board seatEmmett Cunningham· per SEC Form D · $85M raise · filed Dec 2018
Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)
BiotechCambridge, US
Jill C. Milne(Executive Officer, Director)Ian Sanderson(Executive Officer)in
BoardRon Laufer(Director)Jean George(Director)Michael Ross(Director)
Board seatNicholas Galakatos· per SEC Form D · $20.4M raise · filed Mar 2015
Co-investorsLightstone Ventures
HealthtechMt Olive, US
Louis Altieri(Executive Officer)Larry Heaton(Executive Officer)in
BoardSteven C. Adler(Director)David Jenkins(Director)Donald P. Carson(Director)
Board seatKurt Wheeler· per SEC Form D
Co-investorsClarus Ventures
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Board seatScott Requadt· per SEC Form D · $25M raise · filed Aug 2016
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupPolaris PartnersSoleus Capital
Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies.
BiotechHardwareHealthtechMedical DevicesToronto, US
Domenic Serafino(Executive Officer, Director)inKirk Gunhus(Executive Officer)inRoss Portaro(Executive Officer)inAnna Georgiadis(Executive Officer)inMelissa Kang(Executive Officer)inMichael Mandarello(Executive Officer)in
Board seatEmmett CunninghamEmmett Cunningham, Jr.· per SEC Form D · $26M raise · filed Aug 2017
Co-investorsAPERTURE Venture PartnersEssex Woodlands Healthcare PartnersLongitude CapitalHealthQuest Capital
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesSV Health InvestorsSV Life Sciences
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ESSA PharmaSilk TechnologiesVBI Vaccines Inc/BCLycera
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
2 IPOsCalciMedica NASDAQ: CALC www.calcimedica.comNASDAQ: CALCPraxisNASDAQ: PRAX
Portfolio news
latest coverage across their companiesPraxis · investing.com · Aug 17, 2026
Venus Concept · stocktitan.net · Mar 18, 2026
Fund performance · per public LP disclosures · 2
as of Sep 2021| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Clarus Lifesciences II, L.P.LPs: California Public Employees' Retirement System | 2008 | — | 14.7% | 1.84x | 1.79x |
| Clarus Lifesciences I, L.P.LPs: California Public Employees' Retirement System, Michigan Municipal Employees' Retirement System | 2006 | — | 4.0% | 1.26x | 1.15x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Clarus made?
- Clarus has 12 tracked investments, 2 of which have exited.
- Where is Clarus located?
- Clarus is headquartered in Cambridge, US.